4.5 Review

Mitochondrial resetting and metabolic reprogramming in induced pluripotent stem cells and mitochondrial disease modeling

期刊

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
卷 1860, 期 4, 页码 686-693

出版社

ELSEVIER
DOI: 10.1016/j.bbagen.2016.01.009

关键词

Induced pluripotent stem cells; Glycolysis; Metabolic reprogramming; Mitochondrial disease

资金

  1. Ministry of Science and Technology (MOST) of Taiwan Government [MOST103-2314-B-715-001-MY2, MOST104-2314-B-715-003-MY3, MOST103-2321-B-715-001]
  2. Mackay Medical College [MMC1012A10, MMC1012B13, RD1010061, RD1020021, RD1020088, MMC1031B05, RD1030006, RD1030098, RD1040109]
  3. Mackay Memorial Hospital [MMH-MM-10304, MMH-MM-10405, MMH-MM-10505]

向作者/读者索取更多资源

Background: Nuclear reprogramming with pluripotency factors enables somatic cells to gain the properties of embryonic stem cells. Mitochondrial resetting and metabolic reprogramming are suggested to be key early events in the induction of human skin fibroblasts to induced pluripotent stem cells (iPSCs). Scope of review: We review recent advances in the study of the molecular basis for mitochondrial resetting and metabolic reprogramming in the regulation of the formation of iPSCs. In particular, the recent progress in using iPSCs for mitochondrial disease modeling was discussed. Major conclusions: iPSCs rely on glycolysis rather than oxidative phosphorylation as a major supply of energy. Mitochondrial resetting and metabolic reprogramming thus play crucial roles in the process of generation of iPSCs from somatic cells. General significance: Neurons, myocytes, and cardiomyocytes are cells containing abundant mitochondria in the human body, which can be differentiated from iPSCs or trans-differentiated from fibroblasts. Generating these cells from iPSCs derived from skin fibroblasts of patients with mitochondrial diseases or by trans-differentiation with cell-specific transcription factors will provide valuable insights into the role of mitochondrial DNA heteroplasmy in mitochondrial disease modeling and serves as a novel platform for screening of drugs to treat patients with mitochondrial diseases. (C) 2016 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据